EMPLICURE RECEIVES FORMAL NOTIFICATION OF APPROVED US PATENT FOR INHALATION OF PHARMACEUTICALSEmplicure AB has received issue notification from the US Patent and Trademark Office that a formal approval of the inhalation platform of pharmaceuticals will be issued on December 21, 2021. "The United States is an important market for us. The announcement of patent approval for inhaled drugs is extremely gratifying and important, as it strengthens our conditions to develop new unique and patent-protected pharmaceutical products for inhalation", says Torbjörn W. Larsson, CEO of Emplicure.
The patent, U.S. Patent No. 11,202,871 will be valid into 2037. The information about the preliminary approval was published August 19, 2021.
Adviser
Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via [email protected]
For more information, please contact:
|
Anna-Lena Nicolson
CFO, Investor Relations
Phone: +46 (0)72 33 68 68
Email: [email protected]
|
The following documents can be retrieved from beQuoted
PM-Emplicure-receives-formal-approval-of-US-patent-for-inhal.pdf Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at www.emplicure.com
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 